Skip to main content

Primary Amyloidosis clinical trials at UC Irvine
1 research study open to eligible people

  • S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis

    open to eligible people ages 18 years and up

    This phase II trial studies how well isatuximab works in treating patients with primary amyloidosis that has come back or does not respond to treatment. Monoclonal antibodies, such as isatuximab, may interfere with the ability of cancer cells to grow and spread.

    Orange, California and other locations

Last updated: